B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

Medical history has recently been made in a New York City hospital. This month, 21-year-old Sebastien Beauzile became the ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Synthetic Biology is advancing the use of microorganisms as cancer therapies, with scientists engineering bacteria to boost antitumor immunity and deliver ...

Sebastien Beauzile, 21, is the first New Yorker to have received the breakthrough Lyfgenia treatment, according to the New ...

But what it does have is its critical role—albeit underrated—as a biotech hub. Competing with South San Francisco and Boston, ...

Google searches for ‘milk thistle hangover cure’ have surged by 5000% in the past 90 days, and TikTok users are raving about ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

The Mayo Clinic Center for Regenerative Biotherapeutics manufactures a wide range of products for active, early-phase clinical trials.